{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(9)"],"submitter":["Alexis AF"],"funding":["Dermavant Sciences, an Organon Company"],"pubmed_abstract":["Introduction
Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type.Methods
The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluatio"],"journal":["Dermatology and therapy"],"pagination":["2667-2682"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12354664"],"repository":["biostudies-literature"],"pubmed_title":["Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials."],"pmcid":["PMC12354664"],"pubmed_authors":["Rice ZP","Chovatiya R","Piscitelli SC","Armstrong AW","Brown PM","Rubenstein DS","Alexis AF","Soong W","Kircik L","Bhutani T","Tallman AM"],"additional_accession":[]},"is_claimable":false,"name":"Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.","description":"Introduction
Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type.Methods
The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluatio","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-29T19:06:42.141Z","creation":"2026-05-18T03:07:33.058Z"},"accession":"S-EPMC12354664","cross_references":{"pubmed":["40696240"],"doi":["10.1007/s13555-025-01489-w"]}}